Clinical Trials · NCT01300260
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 32
- Start date
- Feb 2011
- Locations
- 1 site, Germany
- Primary endpoint
- Maximum Insulin Concentration (Cmax) - First Phase Response